Somnomed Limited · ASX:SOM
Somnomed — H1 FY2019 Earnings Presentation
19 slides from Somnomed's earnings presentation, Feb 21, 2019
Slide 1: Investor Presentation Half Year FY2019
For personal use only Investor Presentation Half Year FY2019 Improving lives through better sleep
Slide 2: Disclaimer & Regulatory Disclosure
Disclaimer & Regulatory Disclosure For personal use only This document has been prepared as a summary only, and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s
Slide 3: Outline
For personal use only Outline: 1. First-half results summary 2. Vision & market opportunity 3. Financial information 4. Outlook 3
Slide 4: 1. First-half results summary
For personal use only 1. First-half results summary 4
Slide 5: First-half summary
First-half summary For personal use only > SomnoMed’s Core revenues +15% over prior year > Underlying EBITDA $1.6m and +60% over prior year > USA direct revenue result of +12% showing positive growth trends from the new sales and marketing initiatives leading into the second half > Europe first half
Slide 6: 2. Vision & market opportunity
For personal use only 2. Vision & market opportunity 6
Slide 7: Vision
Vision For personal use only SomnoMed will be the leader in the treatment of obstructive sleep apnea and build a fast growing, profitable, global medical device company by: ➢ Developing and providing patient friendly and cost-effective alternative therapies with high levels of patient compliance, im
Slide 8: The SomnoMed opportunity is large
The SomnoMed opportunity is large For personal use only 8
Slide 9: COAT™ Continuous Open Airway Therapy
For personal use only COAT™ “Continuous Open Airway Therapy” 9
Slide 10: SomnoMed's competitive advantage
SomnoMed’s competitive advantage For personal use only > Strong clinical research supporting COAT™ therapy > Comprehensive product range, proprietary materials and designed for patient comfort > Leading brand with over 470,000 patients treated worldwide > Go-to-market strength in both dental and med
Slide 11: 3. Financial information
For personal use only 3. Financial information 11
Slide 12: Total SomnoMed core revenue growth
Financials For personal use only Total SomnoMed core revenue growth 12
Slide 13: Revenue growth by region
Financials For personal use only Revenue growth by region $000 $000 $000 13
Slide 14: Steady margins
Financials For personal use only Steady margins MAS gross margin = device gross margin Group gross margin = device and other revenue stream gross margin 14
Slide 15: EBITDA growth
Financials For personal use only EBITDA growth * EBITDA as adjusted does not include share and option expense, loss on contingent consideration payable and unrealized foreign exchange gain/(loss) ** Underlying EBITDA $1.613m with growth of 60% 15
Slide 16: Financial Summary - AUD $000's SomnoMed core
Financials Financial Summary - AUD $000's SomnoMed core First half comparison FY19 FY18* 1st H 1st H For personal use only % Revenue 28,815 24,959 15% Gros s ma rgi n 17,018 14,736 15% Regi ona l s a l es a nd ma rketing expens es (7,408) (6,749) 10% Regi ona l a dmi ni s tra tive expens es (5,069)
Slide 17: 4. Outlook
For personal use only 4. Outlook 17
Slide 18: Outlook
Outlook For personal use only > Regional : * Europe: - all market fundamentals are good, with consistent revenue growth in all major countries - expected revenue growth of 20% in second half * North America: - direct and managed care revenue growth both moving in the right direction - expected reven
Slide 19: Contact
For personal use only Contact 19